ES2602606T3 - Formulaciones de liberación prolongada que comprenden un derivado de 2-oxo-1-pirrolidina - Google Patents
Formulaciones de liberación prolongada que comprenden un derivado de 2-oxo-1-pirrolidina Download PDFInfo
- Publication number
- ES2602606T3 ES2602606T3 ES09752825.1T ES09752825T ES2602606T3 ES 2602606 T3 ES2602606 T3 ES 2602606T3 ES 09752825 T ES09752825 T ES 09752825T ES 2602606 T3 ES2602606 T3 ES 2602606T3
- Authority
- ES
- Spain
- Prior art keywords
- brivaracetam
- seizures
- oxo
- extended release
- release formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title description 6
- 238000013265 extended release Methods 0.000 title description 2
- 238000009472 formulation Methods 0.000 title description 2
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 abstract description 14
- 229960002161 brivaracetam Drugs 0.000 abstract description 14
- 239000008187 granular material Substances 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 abstract description 7
- 229950000852 seletracetam Drugs 0.000 abstract description 7
- 238000013270 controlled release Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 11
- 229960004002 levetiracetam Drugs 0.000 description 10
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 206010053398 Clonic convulsion Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001787 epileptiform Effects 0.000 description 7
- 238000004880 explosion Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000037012 Psychomotor seizures Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960005152 pentetrazol Drugs 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08105817 | 2008-11-18 | ||
| EP08105817 | 2008-11-18 | ||
| EP09100311 | 2009-06-02 | ||
| EP09100311 | 2009-06-02 | ||
| PCT/EP2009/065270 WO2010057869A1 (en) | 2008-11-18 | 2009-11-17 | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2602606T3 true ES2602606T3 (es) | 2017-02-21 |
Family
ID=41395028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09752825.1T Active ES2602606T3 (es) | 2008-11-18 | 2009-11-17 | Formulaciones de liberación prolongada que comprenden un derivado de 2-oxo-1-pirrolidina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8460712B2 (OSRAM) |
| EP (1) | EP2358361B1 (OSRAM) |
| JP (2) | JP5954889B2 (OSRAM) |
| KR (2) | KR101788804B1 (OSRAM) |
| CN (2) | CN102215828A (OSRAM) |
| AU (1) | AU2009317279B2 (OSRAM) |
| BR (1) | BRPI0921301A2 (OSRAM) |
| CA (1) | CA2741038C (OSRAM) |
| DK (1) | DK2358361T3 (OSRAM) |
| EA (1) | EA019583B1 (OSRAM) |
| ES (1) | ES2602606T3 (OSRAM) |
| HK (1) | HK1198288A1 (OSRAM) |
| HU (1) | HUE030963T2 (OSRAM) |
| IL (1) | IL212271A (OSRAM) |
| MX (1) | MX356281B (OSRAM) |
| PL (1) | PL2358361T3 (OSRAM) |
| PT (1) | PT2358361T (OSRAM) |
| WO (1) | WO2010057869A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032275T2 (en) * | 2008-11-18 | 2017-09-28 | Ucb Biopharma Sprl | Sustained release formulations containing a 2-oxo-pyrrolidine derivative |
| MX2018008021A (es) | 2015-12-30 | 2018-11-09 | Adamas Pharmaceuticals Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. |
| WO2017195144A1 (en) * | 2016-05-12 | 2017-11-16 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| ES3037587T3 (en) * | 2021-05-11 | 2025-10-03 | Advicenne | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
| TR2023017170A1 (tr) * | 2023-12-13 | 2025-06-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Bri̇varasetam i̇çeren bi̇r saşe formülasyonu |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| CN101111245A (zh) * | 2005-01-27 | 2008-01-23 | 阿雷姆贝克有限公司 | 左乙拉西坦延长释放制剂 |
| WO2006088864A1 (en) * | 2005-02-16 | 2006-08-24 | Elan Pharma International Limited | Controlled release compositions comprising levetiracetam |
| US20070298098A1 (en) | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| ES2403069T3 (es) * | 2005-02-22 | 2013-05-13 | Sun Pharma Advanced Research Company Ltd | Composición oral de liberación controlada que contiene levetiracetam |
| CA2600282A1 (en) * | 2005-03-29 | 2006-10-05 | Roehm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
| FR2897267A1 (fr) * | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| BRPI0712325A2 (pt) * | 2006-06-08 | 2012-01-10 | Ucb Pharma Sa | processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal |
| BRPI0716196A2 (pt) * | 2006-08-31 | 2013-11-12 | Eurand Inc | Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos. |
| WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| KR101454056B1 (ko) * | 2007-09-21 | 2014-10-27 | 에보니크 룀 게엠베하 | 에탄올의 영향에 대하여 내성을 가지는 비-오피오이드용 ｐｈ-의존성 조절 방출 제약 조성물 |
| EP2273975B8 (en) | 2008-03-03 | 2014-12-17 | UCB Pharma, S.A. | Pharmaceutical solutions, process of preparation and therapeutic uses |
-
2009
- 2009-11-17 MX MX2011004572A patent/MX356281B/es active IP Right Grant
- 2009-11-17 EA EA201100753A patent/EA019583B1/ru unknown
- 2009-11-17 HU HUE09752825A patent/HUE030963T2/en unknown
- 2009-11-17 US US13/128,950 patent/US8460712B2/en active Active
- 2009-11-17 PT PT97528251T patent/PT2358361T/pt unknown
- 2009-11-17 KR KR1020177000418A patent/KR101788804B1/ko active Active
- 2009-11-17 CN CN2009801455887A patent/CN102215828A/zh active Pending
- 2009-11-17 CA CA2741038A patent/CA2741038C/en active Active
- 2009-11-17 ES ES09752825.1T patent/ES2602606T3/es active Active
- 2009-11-17 AU AU2009317279A patent/AU2009317279B2/en active Active
- 2009-11-17 WO PCT/EP2009/065270 patent/WO2010057869A1/en not_active Ceased
- 2009-11-17 PL PL09752825T patent/PL2358361T3/pl unknown
- 2009-11-17 CN CN201410370727.9A patent/CN104083341A/zh active Pending
- 2009-11-17 BR BRPI0921301A patent/BRPI0921301A2/pt not_active IP Right Cessation
- 2009-11-17 DK DK09752825.1T patent/DK2358361T3/en active
- 2009-11-17 EP EP09752825.1A patent/EP2358361B1/en active Active
- 2009-11-17 JP JP2011543762A patent/JP5954889B2/ja active Active
- 2009-11-17 KR KR1020117014019A patent/KR20110089184A/ko not_active Ceased
-
2011
- 2011-04-12 IL IL212271A patent/IL212271A/en active IP Right Grant
-
2014
- 2014-11-21 HK HK14111805.6A patent/HK1198288A1/xx unknown
-
2015
- 2015-03-31 JP JP2015071166A patent/JP2015143256A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170007528A (ko) | 2017-01-18 |
| EA201100753A1 (ru) | 2012-01-30 |
| CA2741038C (en) | 2015-01-13 |
| KR101788804B1 (ko) | 2017-10-20 |
| MX2011004572A (es) | 2011-06-17 |
| AU2009317279A1 (en) | 2010-05-27 |
| WO2010057869A1 (en) | 2010-05-27 |
| DK2358361T3 (en) | 2016-12-12 |
| IL212271A0 (en) | 2011-06-30 |
| CN102215828A (zh) | 2011-10-12 |
| IL212271A (en) | 2016-10-31 |
| EP2358361A1 (en) | 2011-08-24 |
| MX356281B (es) | 2018-05-22 |
| CA2741038A1 (en) | 2010-05-27 |
| JP2012509356A (ja) | 2012-04-19 |
| PL2358361T3 (pl) | 2017-02-28 |
| US20110274762A1 (en) | 2011-11-10 |
| AU2009317279B2 (en) | 2013-10-24 |
| CN104083341A (zh) | 2014-10-08 |
| HUE030963T2 (en) | 2017-06-28 |
| US8460712B2 (en) | 2013-06-11 |
| PT2358361T (pt) | 2016-11-18 |
| EA019583B1 (ru) | 2014-04-30 |
| JP5954889B2 (ja) | 2016-07-20 |
| JP2015143256A (ja) | 2015-08-06 |
| EP2358361B1 (en) | 2016-09-14 |
| BRPI0921301A2 (pt) | 2015-12-29 |
| KR20110089184A (ko) | 2011-08-04 |
| HK1198288A1 (en) | 2015-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2520990T3 (es) | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina | |
| ES2602606T3 (es) | Formulaciones de liberación prolongada que comprenden un derivado de 2-oxo-1-pirrolidina | |
| ES2511047T3 (es) | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina | |
| ES2486793T3 (es) | Sistema polimérico de administración para una solución a base de prostaglandina no viscosa sin conservantes | |
| ES2981782T3 (es) | Composiciones y métodos para tratar la inflamación crónica y enfermedades inflamatorias | |
| US8563036B2 (en) | Pharmaceutical compositions comprising Brivaracetam | |
| US10172805B2 (en) | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| WO2010015665A3 (en) | Parenteral composition comprising microspheres with a diameter between 10 and 20 microns | |
| WO2018035030A1 (en) | Time release fat-soluble actives | |
| MXPA03011314A (es) | Formulacion farmaceutica para la administracion eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina y sus derivados y pro-farmacos de los mismos. | |
| KR102557719B1 (ko) | 항산화제가 담지된 나노입자를 유효성분으로 포함하는 귀 질환 치료용 약학 조성물 | |
| TW577741B (en) | Novel pharmaceutical combination for treating pain comprising paracetamol and buspirone | |
| RU2015128915A (ru) | Составы лоразепама с замедленным высвобождением | |
| JP2015516449A (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物 | |
| HK1159503B (en) | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative |